March 14, 2017
Kissei Pharmaceutical will collaborate with Maruishi Pharmaceutical on the development and sales of MR13A9, a kappa opioid receptor agonist that Maruishi licensed from US biotech Cara Therapeutics, for the treatment of uremic pruritus in dialysis patients in Japan. Announcing their...read more